By Jonathan Gardner
Published June 15, 2026
The landscape of American pharmaceutical pricing is bracing for a significant regulatory shift. As the federal government prepares for the fourth iteration of its drug-price negotiation program under the Inflation Reduction Act (IRA) of 2022, regulators have signaled a crackdown on a practice critics label as a "loophole." On June 12, 2026, the Centers for Medicare & Medicaid Services (CMS) released a proposed rule for 2029 that aims to ensure that pharmaceutical companies cannot evade price scrutiny simply by shifting patients from intravenous (IV) to subcutaneous (under-the-skin) formulations of existing blockbuster medicines.
This proposed rule represents a pivotal moment in the ongoing tension between federal cost-containment efforts and the commercial "evergreening" strategies employed by the world’s largest pharmaceutical manufacturers.
Main Facts: Closing the Formulation Gap
At the heart of the 2029 proposal is the federal government’s attempt to harmonize how Medicare views different delivery methods of the same therapeutic agent. Historically, manufacturers have maintained that a new delivery method—such as a subcutaneous injection meant to replace a lengthy, hospital-based IV infusion—constitutes a distinct enough product to warrant a separate regulatory path.
The proposed rule for 2029 effectively closes this gap. By ensuring that price protection applies to the active ingredient regardless of the delivery mechanism, CMS is signaling that it will no longer allow the transition from IV to subcutaneous administration to act as a shield against price negotiation. The intent is to prevent companies from "resetting the clock" on patent-protected pricing by shifting the patient population to a newer version of a legacy drug just as the original formulation faces competitive pressure.
Chronology: From the IRA to the 2029 Horizon
To understand the weight of this proposal, one must look at the timeline of the IRA’s implementation:
- August 2022: The Inflation Reduction Act is signed into law, granting Medicare the unprecedented authority to negotiate prices for certain high-cost, high-spend drugs.
- 2024–2025: Initial rounds of negotiations begin, focusing on the first cohorts of Medicare Part D and Part B drugs, setting the precedent for federal intervention in pharmaceutical markets.
- 2026: The first negotiated prices officially take effect, marking a permanent change in the American healthcare economy.
- June 2026: CMS releases the proposed rule for 2029, explicitly addressing the "IV-to-subcutaneous" transition loophole.
- February 1, 2027: CMS is scheduled to release the formal list of 20 drugs subject to price negotiation for the 2029 cycle.
- December 2028: Expected market entry of biosimilar competitors for major oncology blockbusters, a date that creates significant legal and financial uncertainty for the current negotiation process.
Supporting Data: The Mega-Blockbuster Context
While the rule is written in broad regulatory language, industry analysts and investors are keenly aware of the primary targets: oncology giants like Bristol Myers Squibb’s Opdivo and Merck’s Keytruda.
The financial stakes are immense. In 2025, these two drugs alone generated a combined global revenue of approximately $41 billion. Because they are indicated for a wide variety of cancers, they occupy a massive footprint in the Medicare Part B budget.
The Economics of Convenience
The transition to subcutaneous (SC) formulations is not merely a scientific advancement; it is a defensive commercial strategy.
- Efficiency: SC formulations allow for shorter administration times, bypassing the capacity constraints of overcrowded hospital infusion centers.
- Revenue Protection: By converting a patient base from an IV product nearing a "patent cliff" to an SC product, manufacturers attempt to extend their monopoly revenue.
- Market Dynamics: Leerink Partners analyst David Risinger has noted that while biosimilar competition for the original IV versions is expected to arrive in late 2028, it remains unclear if this timing will be sufficient to exempt the new SC formulations from being selected for negotiation.
Official Responses and Stakeholder Positions
The pharmaceutical industry has historically argued that new delivery methods offer genuine patient benefits, including reduced time in the clinic and lower facility fees. Trade groups, such as PhRMA, have previously expressed concerns that aggressive price negotiation policies could stifle innovation in drug delivery and administration.
Conversely, patient advocacy groups and fiscal hawks in Washington have praised the move. They argue that the "convenience" offered by SC formulations is often used as a pretext to maintain premium pricing long after the underlying molecule has faced its initial patent expiration. By closing the loophole, CMS is asserting that the value of the medicine—not the method of delivery—is what matters to the taxpayer-funded Medicare program.
Implications: A New Era of Negotiation
The implications of this proposed rule are wide-ranging, affecting everything from R&D strategy to the long-term sustainability of Medicare.
1. The "Deselection" Uncertainty
A significant, if complex, element of the proposed rule is the provision that drugs facing generic or biosimilar competition can be "deselected" from the negotiation process. This creates a high-stakes game of "cat and mouse." If a manufacturer can successfully pivot a large percentage of its patients to an SC formulation before biosimilars hit the market, they may be able to keep the drug—and its price—out of the scope of CMS negotiations. However, if the rule successfully captures these SC forms under the umbrella of the original drug, that strategy becomes significantly less viable.
2. Impact on Clinical Innovation
Critics of the rule warn that if manufacturers are disincentivized from developing more patient-friendly delivery systems because of potential price caps, it could lead to a decline in "incremental innovation." If an SC formulation is destined to be immediately subject to the same price constraints as an older IV version, the return on investment for the R&D required to develop that delivery system drops significantly.
3. The Future of Medicare Spending
For the Medicare program, this is about fiscal predictability. By ensuring that the negotiation process covers the "active ingredient" across all formulations, the government is preventing the erosion of savings that would otherwise occur if manufacturers were allowed to bypass negotiations through product line extensions.
4. Legal Challenges Expected
Given the magnitude of the revenues involved, it is almost certain that this rule will face legal challenges. Pharmaceutical companies are likely to argue that the federal government is overstepping its authority by effectively regulating products that have not yet reached their own independent "patent cliff." The definition of what constitutes a "new" drug versus a "reformulated" drug will likely be the primary battleground in federal courtrooms over the next 18 to 24 months.
Conclusion
As the February 2027 deadline for the 2029 negotiation list approaches, the healthcare sector is entering a period of heightened regulatory scrutiny. The proposed rule regarding IV-to-subcutaneous transitions is more than a technical adjustment to CMS guidelines; it is a fundamental assertion of federal power in the pharmaceutical marketplace.
Whether this move successfully reins in drug costs without chilling the development of next-generation drug delivery remains the central question. For now, the industry is left in a state of "wait and see," balancing the need to offer better patient experiences against a regulatory environment that is increasingly focused on the bottom line. The 2029 negotiation cycle promises to be the most contentious yet, as the government seeks to ensure that the transition to new formulations is a benefit to the patient, not just a shield for the manufacturer’s revenue.
